Remove tag patient-registries
article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

When asked by pharmaphorum why product sales are expected to be so high in this area, a spokesperson for Evaluate explained: “For many rare diseases, there is high unmet need which results in high levels of use of orphan products in the eligible patient groups, and these groups are often larger than anticipated once treatments become available.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RFID: The future of smart labelling?

Pharmaceutical Technology

The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Twenty years ago, the cost of implementing RFID tags and the ecosystem (software) was much more expensive than today.

Labelling 105
article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

Due to shipping and manufacturing requirements, the time from a patient being included in the CAR T programme to receiving therapy can be several weeks. As a result, many patients waiting for the CAR T cells to be infused will need additional therapy (bridging therapy) against the malignance. 6-8 Clinical recommendations also change.